Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toca 511 and Toca FC in Newly Diagnosed High Grade Glioma
NCT02598011Phase 1Withdrawn
- Sponsor
- Tocagen
- Start
- Jan 2017
- Primary completion
- Nov 2022
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
01
Overview
Phase 1, open-label trial of vocimagene amiretrorepvec and flucytosine in high-grade glioma (HGG) (2 arms), sponsored by Tocagen. Primary endpoint: Dose limiting toxicities at 12 weeks. Planned start Jan 2017; status: withdrawn.
02
Drugs
vocimagene amiretrorepvecflucytosine
03
Conditions
high-grade glioma (HGG)
Beyond the preview
Go deeper on NCT02598011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02598011.